Neurologic and Metabolic Disorders It may also serve as adjunctive therapy in: Chronic fatigue syndromes Diabetic neuropathy Insulin resistance or metabolic syndrome Age-related mitochondrial decline Dosing and Administration Route : IM injection (preferred for general use), IV infusion (under clinical guidance) Typical IM dose : 5001,000 mg, 13 times per week IV use : 12 grams diluted in compatible carrier solution (e.g., saline), infused over 3060 minutes Dosing frequency is patient-specific and may be adjusted based on clinical response , exercise load , or lab values Safety and Considerations L-Carnitine is generally well tolerated when administered properly
Beck EJ, Tosh SM, Batterham MJ, Tapsell LC, Huang XF
Ergonomic Build: Lightweight, portable, and designed for low-force activation to improve patient compliance
Currently, Ivm offers injectable GLP-1 medications (semaglutide and tirzepatide) through licensed compounding pharmacies